SAU Cancer Metastasis JRF Opening


Junior Research Fellow (JRF) 

CSIR funded project entitled “Investigating the role of exogenous ATP in cancer metastasis” under the supervision of Dr. Ravi Shankar Akundi, Faculty of Life Sciences and Biotechnology, South Asian University, New Delhi. 

Fellowship is as per CSIR rules. 

Qualifications: 

The minimum qualifications are BS 4 years programme/ BPharm/ MBBS/ Integrated BS-MS/ MSc or equivalent degree in any area of life sciences, with 55% marks AND passing of National Eligibility Test (NET) conducted jointly by CSIR and UGC. 

Candidates who have qualified in the GATE test may also apply. Non-NET or Non-GATE qualified candidates cannot apply for this post. 

The upper age limit for JRF shall be 28 years as on the day on which the application is made. However, a smaller relaxation in age limit may be considered in case of applicants who are suitably qualified based on recommendations of the Selection Committee. 

Experience in mammalian cell culture techniques and molecular biology techniques such as cloning, PCR and antibody-based methods will be advantageous. 

Application Procedure: A covering letter along with the latest CV and contact address (including email) of at least two referees should be emailed to akundi.ravi@gmail.com by July 07, 2017

Copy of the proof of NET/GATE qualification and latest educational qualification should be attached. Relevant documents such as proof of experience, published papers, etc. may also be sent. Selected candidates will be informed on/before July 14, 2017. 

Details about the date of interview which will be held at SAU will be emailed separately to the selected candidates.

Important Note: Applications received after July 07, 2017 will not be screened. Email will be sent only to the shortlisted candidates. No TA/DA will be available for attending the interview. The position is temporary and is extendable only upon satisfactory performance review. Email where applications have to be sent before July 07, 2017: akundi.ravi@gmail.com

Post a Comment

0 Comments